Pleiotropic effects of antidiabetic agents on renal and cardiovascular outcomes: a meta-analysis of randomized controlled trials.

International Urology and Nephrology
Api ChewcharatPaweena Susantitaphong

Abstract

This meta-analysis was conducted to examine the pleiotropic effects of all available antidiabetic agents except insulin for type 2 diabetes on renal and cardiovascular outcomes. A systematic literature search was performed in PubMed, EMBASE, and Cochrane database to identify randomized-controlled trials which compared the effectiveness between all antidiabetic agents apart from insulin regarding all aspects of renal and cardiovascular outcomes. Random effect model was utilized to compute for hazard ratio. Nineteen articles with 140,851 participants were included in this meta-analysis. When compared with placebo, SGLT-2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors exhibited significantly lower hazard ratios of progression of albuminuria. SGLT-2 inhibitors and DPP-4 inhibitors showed a significantly higher hazard ratio of regression of albuminuria. Only SGLT-2 inhibitors illustrated significantly lower hazard ratios of doubling of serum creatinine and incidence of renal replacement therapy (RRT). A significantly lower hazard ratio of composite renal outcome was detected in both SGLT-2 inhibitors and GLP-1 agonists. A significantly lower hazard ratio of all-cause mortality was identified in SGLT-2 inhibitors and GLP-1 agonist....Continue Reading

References

Oct 4, 2013·International Journal of Endocrinology·Martin HaluzíkIvan Rychlík
Jun 4, 2014·The Journal of Clinical Investigation·Kimberly ReidyKatalin Susztak
May 12, 2015·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Mark E CooperMaximilian von Eynatten
Jun 9, 2015·The New England Journal of Medicine·Jennifer B GreenUNKNOWN TECOS Study Group
Dec 3, 2015·The New England Journal of Medicine·Marc A PfefferUNKNOWN ELIXA Investigators
Jun 15, 2016·The New England Journal of Medicine·Christoph WannerUNKNOWN EMPA-REG OUTCOME Investigators
Sep 17, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN SUSTAIN-6 Investigators
Nov 1, 2016·Diabetes Care·Ofri MosenzonItamar Raz
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Aug 31, 2017·The New England Journal of Medicine·Johannes F E MannUNKNOWN LEADER Steering Committee and Investigators
Sep 5, 2017·Nature Reviews. Nephrology·Marcel H A MuskietDaniël H van Raalte
Sep 15, 2017·The New England Journal of Medicine·Rury R HolmanUNKNOWN EXSCEL Study Group
Oct 22, 2017·Clinical Journal of the American Society of Nephrology : CJASN·Leila R ZelnickIan H de Boer
May 8, 2018·Kidney International·Hiddo J L HeerspinkDavid Z I Cherney
Jun 6, 2018·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Radica Z AlicicKatherine R Tuttle
Nov 13, 2018·The New England Journal of Medicine·Stephen D WiviottUNKNOWN DECLARE–TIMI 58 Investigators
Nov 13, 2018·JAMA : the Journal of the American Medical Association·Julio RosenstockUNKNOWN CARMELINA Investigators
Feb 2, 2019·Clinical Diabetes : a Publication of the American Diabetes Association·UNKNOWN American Diabetes Association
Apr 17, 2019·The New England Journal of Medicine·Vlado PerkovicUNKNOWN CREDENCE Trial Investigators
Jun 5, 2019·Medicina·Eulalia Valentina GrecoSalvatore De Cosmo
Sep 10, 2019·European Heart Journal·Francesco CosentinoUNKNOWN ESC Scientific Document Group
Dec 22, 2019·Diabetes Care·UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.